Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Total Current Liabilities of $231.6 million for Q4 2025, up 7.03% year-over-year from $216.4 million in Q4 2024, and up 7.03% quarter-over-quarter from $216.4 million in Q4 2024.
Telix Pharmaceuticals (TLX) Total Current Liabilities (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Total Current Liabilities for 3 consecutive years, with $231.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 7.03% year-over-year to $231.6 million; the TTM figure through Dec 2025 stood at $231.6 million (up 7.03% YoY), while the FY2025 annual figure was $231.6 million, up 12.94% from the prior year.
- Total Current Liabilities grew to $231.6 million in Q4 2025 per TLX's latest filing, from $216.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $231.6 million in Q4 2025 and bottomed at $107.5 million in Q4 2023.
- Historically, Total Current Liabilities has averaged $185.2 million across 3 years, with a median of $216.4 million in 2024.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 101.39% — and 2025, when it climbed 7.03%.
- Telix Pharmaceuticals' Total Current Liabilities stood at $107.5 million in 2023, then surged by 101.39% to $216.4 million in 2024, then rose by 7.03% to $231.6 million in 2025.
- Business Quant data shows TLX's Total Current Liabilities at $231.6 million in Q4 2025, $216.4 million in Q4 2024, and $107.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 231.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 231.62 Mn |
| Dec 31, 2024 | 216.40 Mn |
| Dec 31, 2023 | 107.46 Mn |